Phosphorylation Profile Kinase Activity NSCLC Treatment Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for non-small cell lung carcinoma (NSCLC) lack effective biomarkers for predicting patient response to targeted pharmacotherapy, leading to undesirable side effects and ineffective treatments due to the need for invasive lung tissue biopsies and limited efficacy of existing therapies.
Innovation Solution
A method involving the measurement of kinase activity in blood samples by contacting them with protein kinase substrates to generate phosphorylation profiles, which determine the response of NSCLC patients to specific medicaments such as Nivolumab, allowing for the prediction of treatment outcomes and resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If lung tissue biopsy is performed for diagnosis and treatment monitoring, then diagnostic accuracy is improved, but patient discomfort and invasiveness increase
Solution Approach 1:
The invention extracts the necessary diagnostic information (kinase activity and phosphorylation profile) from easily accessible blood samples instead of requiring lung tissue biopsy. This extracts the essential diagnostic function from the invasive procedure while maintaining accuracy.
Solution Approach 2:
The invention uses blood samples as an intermediary substance that reflects the molecular characteristics of the tumor. The phosphorylation profile in blood serves as a mediator that provides diagnostic information about NSCLC without directly sampling the tumor tissue.
2Adaptability or versatility
If standard chemotherapy is administered to NSCLC patients, then treatment coverage is improved, but treatment efficacy decreases due to lack of response prediction
Solution Approach 1:
The invention performs preliminary analysis of the patient's phosphorylation profile before treatment initiation to predict response to targeted therapies. This preliminary action enables selection of effective treatments in advance, avoiding ineffective chemotherapy and improving overall treatment efficacy.
Solution Approach 2:
The invention changes the parameter used for treatment selection from general clinical criteria to specific molecular parameters (phosphorylation levels of IGF1R, MET, and other kinases). This parameter change enables precise prediction of treatment response and optimizes therapy selection.
3Speed
If targeted therapy is selected without biomarker prediction, then treatment speed is improved, but side effects increase due to ineffective treatment
Solution Approach 1:
The invention performs rapid phosphorylation profiling and biomarker analysis before treatment initiation to predict response. This preliminary action enables immediate selection of effective targeted therapy, maintaining treatment speed while avoiding side effects from ineffective treatments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables accurate and non-invasive prediction of patient response to targeted pharmacotherapy, reducing side effects and improving treatment efficacy by identifying suitable therapies for NSCLC patients.
Implementation Method 1
measuring the kinase activity of a blood sample by contacting the sample with at least one protein kinase substrate, thereby providing a phosphorylation profile of the sample
Data Source
AI summary
The present invention relates to a method for determining or predicting the response of a patient diagnosed with non-small-cell lung carcinoma to targeted pharmacotherapy. The present invention also aims to provide methods and devices for predicting the response of patients diagnosed with non-small-cell lung carcinoma to specific medicaments. More specifically, the present invention provides methods which measure kinase-activity by studying phosphorylation levels and profiles and inhibitions thereof by drugs in blood samples of said patients.